



**Environmental  
Science**  
Processes & Impacts

**Increased cytotoxicity of Pb<sup>2+</sup> with co-exposures to a  
mitochondrial uncoupler and mitochondrial calcium  
uniporter inhibitor**

Journal:	<i>Environmental Science: Processes &amp; Impacts</i>
Manuscript ID	EM-COM-05-2023-000188.R1
Article Type:	Communication

SCHOLARONE™  
Manuscripts

**Environmental Significance:**

While the majority of real-world exposures involve multiple chemicals, the toxicological knowledge base for understanding combined exposures lags as most studies use single-chemical exposures.  $\text{Pb}^{2+}$  exposure is widespread, causes very serious health effects, and is associated with profound environmental health concerns. Many environmental pollutants and pharmaceuticals, including  $\text{Pb}^{2+}$ , cause mitochondrial dysfunction. We observed increased toxicity of  $\text{Pb}^{2+}$  in combination with two mechanistically distinct mitochondrial toxicants. It is crucial that we understand how co-exposures influence chemical toxicity so that proper regulatory action can be taken to protect human and ecosystem health.

## Increased cytotoxicity of $Pb^{2+}$ with co-exposures to a mitochondrial uncoupler and mitochondrial calcium uniporter inhibitor

Pooja Lalwani<sup>1</sup>, Dillon E. King<sup>1</sup>, Katherine Morton<sup>1</sup>, Nelson A. Rivera Jr<sup>2</sup>, Javier Huayta<sup>1</sup>, Heileen Hsu-Kim<sup>2</sup>, and Joel N. Meyer<sup>1‡</sup>

<sup>1</sup>Nicholas School of Environment, Duke University

<sup>2</sup>Pratt School of Engineering, Duke University

‡ Correspondence:

308 Research Drive, A354 LSRC Building

Durham, NC 27708

(919) 613-8109

[joel.meyer@duke.edu](mailto:joel.meyer@duke.edu)

### Abstract:

Lead ( $Pb^{2+}$ ) is an important developmental toxicant. The mitochondrial calcium uniporter (MCU) imports calcium ions using the mitochondrial membrane potential (MMP), and also appears to mediate the influx of  $Pb^{2+}$  into the mitochondria. Since our environment contains mixtures of toxic agents, it is important to consider multi-chemical exposures. To begin to develop generalizable, predictive models of interactive toxicity, we developed mechanism-based hypotheses about interactive effects of  $Pb^{2+}$  with other chemicals. To test these hypotheses, we exposed HepG2 cells (human liver) to  $Pb^{2+}$  alone and in mixtures with other mitochondria-damaging chemicals: carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP), a mitochondrial uncoupler that reduces MMP, and Ruthenium Red (RuRed), a dye that inhibits the MCU. After 24 hours,  $Pb^{2+}$  alone, the mixture of  $Pb^{2+}$  and RuRed, and the mixture of  $Pb^{2+}$  and FCCP caused no decrease in cell viability. However, the combination of all three exposures led to a significant decrease in cell viability at higher  $Pb^{2+}$  concentrations. After 48 hours, the co-exposure to elevated  $Pb^{2+}$  concentrations and FCCP caused a significant decrease in cell viability, and the mixture of all three showed a clear dose-response curve with significant decreases in cell viability across a range of  $Pb^{2+}$  concentrations. We performed ICP-MS on isolated mitochondrial and cytosolic fractions and found no differences in  $Pb^{2+}$  uptake across exposure groups, ruling out altered cellular uptake as the mechanism for interactive toxicity. We assessed MMP following exposure and observed a decrease in membrane potential that

1  
2  
3 corresponds to loss of cell viability but is likely not sufficient to be the causative mechanistic  
4 driver of cell death. This research provides a mechanistically-based framework for understanding  
5  $Pb^{2+}$  toxicity in mixtures with mitochondrial toxicants.  
6  
7  
8  
9

## 10 **Introduction:**

11  
12 Heavy metals are ubiquitous in our environment due to both natural sources and  
13 anthropogenic actions. Historically, significant sources of  $Pb^{2+}$  exposure have been  $Pb^{2+}$ -based  
14 paints and the addition of  $Pb^{2+}$  to gasoline <sup>1,2</sup>. While the use of  $Pb^{2+}$  for these purposes is now  
15 banned, some  $Pb^{2+}$  derived from gasoline remains in the soil and contributes to exposure along  
16 with  $Pb^{2+}$  contaminated paint in older homes <sup>2,3</sup>. Additional sources of exposure come from  
17 drinking water impacted by legacy water distribution systems, produce grown in  $Pb^{2+}$ -  
18 contaminated soil, some traditional medications, and occupational exposures associated with a  
19 variety of industrial processes <sup>4,5</sup>. Within the population, exposure to  $Pb^{2+}$  occurs  
20 disproportionately, with some demographic groups exposed to  $Pb^{2+}$  more than others. Studies  
21 have shown differential exposure across racial and ethnic groups, with Black children in the US  
22 being more likely to have elevated blood lead levels (BLL) <sup>6</sup>. It is important to note that public  
23 health officials have determined that no safe level of  $Pb^{2+}$  exposure can be established for  
24 children <sup>7</sup>.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

36 At low levels of exposure,  $Pb^{2+}$  toxicity predominantly impacts the nervous system.  $Pb^{2+}$   
37 can inhibit the absorption of dopamine <sup>8</sup>, a crucial neurotransmitter. Children are especially  
38 vulnerable to the harmful effects of  $Pb^{2+}$  as they are more likely to be directly in contact with  
39 sources of  $Pb^{2+}$ , for example, by ingesting paint chips, and because their nervous systems are still  
40 developing. Developing brains are more susceptible to  $Pb^{2+}$  health effects and there is an inverse  
41 relationship between IQ levels, attentiveness, and BLL <sup>8</sup>. Occupational exposures to  $Pb^{2+}$  have  
42 also been correlated with changes in the peripheral nervous system as well as the circulatory and  
43 excretory systems <sup>9,10</sup>.  
44  
45  
46  
47  
48  
49  
50

51 Mitochondria are complex organelles that play a large role in cellular energy production  
52 and metabolism. Beyond energy production, mitochondria are crucial to maintaining cellular  
53 health due to their diverse roles in signaling pathways that directly regulate ion homeostasis,  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 immune responses, apoptosis, and many other processes <sup>11</sup>. Perturbations to mitochondrial health  
4 and homeostasis are associated with a variety of diseases such as diabetes, Parkinson's disease,  
5 Alzheimer's Disease, and many more. Mitochondrial health throughout development is also  
6 crucial to proper neurodevelopment. Many environmental chemicals cause mitochondrial  
7 dysfunction through a variety of mechanisms <sup>12, 13</sup>. Although not all of the targets of  $Pb^{2+}$  are  
8 mitochondrial, many are, such that mitochondria are of particular interest to understanding  $Pb^{2+}$   
9 toxicity. For example,  $Pb^{2+}$  disrupts heme synthesis, which occurs in mitochondria, and  $Pb^{2+}$  has  
10 been shown to inhibit the activity of complex III in the electron transport chain and decrease  
11 ATP production <sup>14</sup>.  
12  
13  
14  
15  
16  
17  
18  
19

20  $Pb^{2+}$  is able to enter the cell through calcium mimicry <sup>15-17</sup>.  $Pb^{2+}$  can replace calcium in  
21 processes that require calcium itself, including for example calcium uptake into mitochondria,  
22 binding to intestinal calcium-binding protein, and Ca-ATPase activity in human red blood cells  
23 <sup>18</sup>. In many of these instances,  $Pb^{2+}$  exhibits a higher affinity of binding than  $Ca^{2+}$  ions to ligand  
24 receptor sites, resulting in a disruption of calcium homeostasis and ultimately toxic effects on  
25 bone density <sup>18</sup>, the nervous system, and the endocrine system <sup>19</sup>. Given the known mechanistic  
26 drivers of  $Pb^{2+}$  toxicity such as disruptions in calcium homeostasis and mitochondrial  
27 mechanisms such as the inhibition of electron transport chain complexes, we are able to employ  
28 hypothesis-based mixture testing to advance predictive toxicology. Specifically, we can use  
29 additional environmental compounds that disrupt mitochondrial function and calcium  
30 homeostasis to look for interactions with  $Pb^{2+}$  toxicity.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 The mitochondrial calcium uniporter (MCU) is a major pathway for calcium's uptake  
42 into the mitochondria <sup>20</sup>, and it has previously been shown that the MCU is an entry point for  
43  $Pb^{2+}$  into the mitochondria as well <sup>15, 21</sup>. The MCU imports calcium using the mitochondrial  
44 membrane potential (MMP) <sup>22</sup>. Ruthenium Red (RuRed, chemical structure shown in Figure  
45 S1A) is a well-studied inhibitor of the MCU that decreases calcium uptake <sup>23</sup> by binding to the  
46 uniporter and preventing the opening of the channel for calcium to flow into the mitochondria.  
47 We are exposed to other chemical inhibitors of the MCU in the environment, including some  
48 inorganic salts and antibiotics such as doxycycline <sup>24</sup>. RuRed can be used as a mechanistic tool to  
49 determine sites of the entry of  $Pb^{2+}$  into the mitochondria <sup>21</sup>, but also as a representative  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 compound of other environmental chemicals that might have similar interactions with  $Pb^{2+}$ .  
4 Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP, chemical structure shown in  
5 Figure S1B), a mitochondrial uncoupler, decreases the proton motive force (assessed as MMP)  
6 by shuttling the flow of protons back from the intermembrane space to the mitochondrial matrix  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

$^{25}$ . This proton motive force, created by the electron transport chain, is used for mitochondrial uptake of many compounds, including calcium  $^{23}$ . Mitochondrial uncouplers are a prevalent class of mitochondrial toxicants; recently, a high-throughput screening identified 1,250 uncouplers of oxidative phosphorylation  $^{26}$ . Examples of mitochondrial uncouplers in our environment include CO-releasing molecules, such as synthetic polymers, sevoflurane, and free fatty acids  $^{27}$ . Both FCCP and RuRed have been shown to decrease calcium uptake into the mitochondria  $^{23}$ , and given that the entry of  $Pb^{2+}$  likely occurs through calcium channels  $^{15}$ , it is important to understand how exposure to uncouplers and MCU inhibitors might interact with  $Pb^{2+}$ .

In this study, we sought to characterize the cytotoxicity of  $Pb^{2+}$  in the presence of the mitochondrial toxicants RuRed and FCCP. We utilized HepG2 cells, a human hepatoma cell line commonly used for screening compounds for mitochondrial toxicity  $^{28,29}$ , to establish dose response curves assessing cell viability across a range of  $Pb^{2+}$  doses alone or in combination with FCCP and/or RuRed. Additionally, we analyzed  $Pb^{2+}$  content of cell components to determine if these exposures altered  $Pb^{2+}$  entry into the mitochondria, and assessed alterations in MMP following exposure. Our results demonstrate clearly increased cytotoxicity of  $Pb^{2+}$  associated with mixtures, further highlighting the importance of understanding how the toxicity of compounds may change based on their co-exposures. To provide adequate regulation of chemicals, we must also consider how they influence biologic systems when in mixtures, as we are never exposed to single chemicals on their own.

## Methods:

### *Cell Culture*

HepG2 cells were cultured in high-glucose DMEM (Invitrogen 11995-065) supplemented with 1 mM HEPES (Gibco 15630-080), 1mM sodium pyruvate (Gibco 11360-070), 10 % Fetal Bovine Serum (HyClone 30071.03), and 1% penicillin-streptomycin (Gibco 15140-122). Cells

1  
2  
3 were maintained at 37°C in vented T75 flasks in a humidified incubator with 5% CO<sub>2</sub>. Cells  
4 were routinely tested for mycoplasma and STR profiled at the Duke Cell Culture Facility.  
5  
6  
7

### 8 *Determining FCCP-induced mitochondrial uncoupling*

9

10 To determine the level of FCCP-induced uncoupling in HepG2 cells, a Seahorse XFe24  
11 Extracellular Flux Analyzer was used. Briefly, 25,000 cells were plated on Seahorse XF24 V7  
12 PS cell culture microplates and cultured overnight. Cells were washed by changing the medium  
13 with an unbuffered assay medium (pH 7.4) containing 1 mM pyruvate and 2 mM glutamine  
14 (Agilent Technologies), supplemented with 17 mM glucose. Cells were put in a 37°C incubator  
15 without CO<sub>2</sub> for an hour. Basal oxygen consumption rate (OCR) was measured, followed by the  
16 injection of a DMSO control, 0.05, 0.1, 0.5, or 1 μM FCCP. An additional injection of Hoechst  
17 33342 was used to stain nuclei. After the assay, a Keyence BZ-X710 fluorescent microscope was  
18 used to count the nuclei. Seahorse OCR data was normalized to the number of cells, determined  
19 by the nuclei count. Experiments were performed in technical triplicate and three biological  
20 replicates were completed, separated by passage number and date. To assess the length of time  
21 that mitochondria remain uncoupled in the presence of FCCP, a Seahorse XFe24 Extracellular  
22 Flux Analyzer was used as previously described. Basal OCR was determined followed by the  
23 injection of a DMSO control or 1 μM FCCP. Following the injection, OCR was monitored for 24  
24 hours. Given that Seahorse instruments are not able to program a run for more than 12 hours, two  
25 12-hour assays were performed back-to-back and the data from the two were combined. OCR  
26 data was normalized to cell count, as described previously.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

### 41 *Cell Viability*

42

43 To assess cell viability, 10,000 HepG2 cells were plated in black clear-bottom 96-well  
44 plates and allowed to adhere overnight. Cells were then dosed with their appropriate treatment:  
45 DMSO control, aqueous Pb<sup>2+</sup> concentrations of 0.1, 2, 10, 25, and 50 μM alone or in  
46 combination with mixtures of 1 μM FCCP, 5 μM RuRed, and a Ca<sup>2+</sup>supplementation. Lead stock  
47 solutions were made from a trace-metal basis lead acetate salt (Millipore Sigma 316512).  
48 Aqueous lead species are referred to as Pb<sup>2+</sup> throughout the text. The addition of a  
49 Ca<sup>2+</sup>supplementation was performed by supplementing cell culture media with calcium chloride  
50 (Sigma C7902) to reach a final concentration of 3.6 mM, twice as high as typical DMEM media  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 30. Experiments were performed in technical triplicate and three biological replicates were  
4 completed for all doses. The 24- and 48-hour dose responses were analyzed at their respective  
5 time points. Cell viability was assessed using the alamarBlue HS Cell Viability Reagent  
6 (Invitrogen) and a FLUOstar Optima microplate reader.  
7  
8  
9

### 10 11 12 *Analysis of Lead Uptake*

13 To study the uptake of  $\text{Pb}^{2+}$  into the mitochondria and the alterations of  $\text{Pb}^{2+}$  uptake with  
14 additional exposures, inductively coupled plasma mass spectrometry (ICP-MS) was used to  
15 quantify  $\text{Pb}^{2+}$  content from isolated mitochondrial and cytosolic fractions. Samples were  
16 prepared by growing HepG2 cells in T75 flasks and exposing them to their appropriate treatment  
17 for 48 hours (i.e., at the highest 50  $\mu\text{M}$   $\text{Pb}^{2+}$  exposure dose described in the Cell Viability  
18 experiment). Cells were then trypsinized and harvested for mitochondrial isolation using the  
19 Mitochondrial Isolation Kit (Thermo Scientific 89874). Data were normalized for protein content  
20 determined by a Pierce BCA Protein Assay Kit (Thermo Scientific 23225). Mitochondrial and  
21 cytosolic isolation samples were processed by heated acid digestion with 0.1 mL of nitric acid  
22 (trace metal grade, Fisher Scientific) per 0.075 mL of sample. The mixture was heated on a hot  
23 block (Environmental Express) at 95°C for two hours and then diluted to 0.5 mL after cooling.  
24 Aliquots of the digestates were diluted with 2% nitric acid/0.5% hydrochloric acid (v/v) diluent  
25 and spiked with  $^{45}\text{Sc}$  and  $^{209}\text{Bi}$  internal standards prior to instrumental analysis. Pb, Mg, and Na  
26 analysis was performed in He collision gas mode and Ca analysis in  $\text{H}_2$  reaction gas mode by  
27 ICP-MS (Agilent 7900). The instrument calibration was performed with a multi-element  
28 standard (Spex Certiprep) and verified by a second source reference (CRM-TMDW-A, High  
29 Purity Standards). Trace metal grade acids and 18.2 M $\Omega$  water (Millipore MilliQ) were used to  
30 prepare reagents and dilutions.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

### 46 *Mitochondrial Membrane Potential*

47 To assess MMP, 50,000 HepG2 cells were plated in black clear-bottom 96-well plates  
48 and allowed to adhere overnight. Cells were then dosed with their appropriate treatment: DMSO  
49 control, 0.1, 2, 10, 25, and 50  $\mu\text{M}$   $\text{Pb}^{2+}$  acetate (Sigma 316512) alone or in combination with  
50 mixtures of 1  $\mu\text{M}$  FCCP, 5  $\mu\text{M}$  RuRed, or both. Cells were exposed to their respective treatment  
51 for either 6 hours or 24 hours, then washed 3 times with phosphate buffered saline (PBS), and  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 exposed to 100 nM tetramethylrhodamine, ethyl ester (TMRE) and 75 nM Mitotracker green in  
4 PBS for 30 minutes. Cells were then washed three times, covered with PBS, and imaged on a  
5 Keyence BZ-X710 fluorescence microscope at  $545\pm 25$  nm excitation and  $605\pm 70$  nm emission  
6 for TMRE staining and  $470\pm 40$  nm excitation and  $525\pm 50$  nm for Mitotracker green staining.  
7  
8  
9

10 Fluorescent images acquired in both green and red channels were analyzed with a  
11 custom-built MATLAB (version R2020b) script. A binary mask was generated from the green  
12 channel image by binarization using the adaptive threshold method, and smoothing of features  
13 using morphological operations (erosion, dilation, and deletion of background objects).  
14 Fluorescence intensity in the corresponding red channel image was determined by extracting  
15 intensity values with the 'regionprops' operation using the regions segmented in the green  
16 channel binary mask. Similarly, a background value was determined for the red channel image  
17 using the complement of the green channel binary mask. Mean intensity values were determined  
18 as the subtraction of the background value from the fluorescent intensity value of each image.  
19 Finally, these values were stored and printed in a MS Excel 2013 worksheet.  
20  
21  
22  
23  
24  
25  
26  
27  
28

### 29 *Statistical Analysis*

30  
31 All experiments were replicated at least three times. For Seahorse experiments, OCR was  
32 normalized to cell counts and results were calculated as a percent increase in OCR from the basal  
33 respiration rate. For the assessment of  $Pb^{2+}$  uptake, data was analyzed via one-way ANOVA with  
34 a Dunnett's post-hoc test for multiple comparisons. For the assessment of dose-responses and  
35 mitochondrial membrane potential, data was analyzed via two-way ANOVA with a Dunnett's  
36 post-hoc test for multiple comparisons. For all graphs, error bars represent the standard error of  
37 the mean (SEM). All statistical analysis was performed using GraphPad Prism.  
38  
39  
40  
41  
42  
43  
44

## 45 **Results & Discussion:**

### 46 *FCCP induces sustained mitochondrial uncoupling*

47  
48 Uncouplers depolarize mitochondria by facilitating the flow of protons across the inner  
49 mitochondrial membrane. In response, cells increase oxygen consumption by the electron  
50 transport chain in an effort to maintain the proton gradient. This can be directly measured by  
51 assessing oxygen consumption using a Seahorse XF analyzer. To determine optimal FCCP  
52 concentrations for mixture studies, we sought a concentration that caused a significant level of  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 uncoupling but was non-cytotoxic to the cells. We observed increases in the oxygen consumption  
4 rate with concentrations of 0.5 and 1  $\mu\text{M}$  FCCP (**Figure S2A**) 1 hour after exposure, and opted  
5 to use 1  $\mu\text{M}$  FCCP exposures for our studies given the robust increase in oxygen consumption  
6 rate that was observed. To determine if FCCP causes sustained uncoupling upon exposure, we  
7 monitored the oxygen consumption rate of HepG2 cells following a 1  $\mu\text{M}$  FCCP exposure for 24  
8 hours. We found that oxygen consumption declined over the course of 24 hours in the  
9 instrument, likely because the Seahorse instrument is not equipped for the long-term culturing of  
10 mammalian cells, but that cells exposed to FCCP did exhibit sustained uncoupling, as evidenced  
11 by the increase in OCR compared to that of the control, for the duration of the experiment  
12 (**Figure S2B**).

### 21 *Mixtures containing FCCP or RuRed and FCCP increase cytotoxicity of $\text{Pb}^{2+}$*

22  
23 To determine the impact of  $\text{Pb}^{2+}$  alone, in mixture with FCCP, RuRed, or both, we  
24 performed a series of dose-response curves for 24- and 48-hour exposures. The concentration of  
25 RuRed used, 5  $\mu\text{M}$ , was selected based on previous literature indicating that this dose was non-  
26 cytotoxic and inhibited the MCU<sup>31</sup>. We first confirmed that FCCP alone and RuRed alone are  
27 non-cytotoxic compounds at these concentrations, as indicated by no decreases in cell viability at  
28 24 or 48 hours (**Figure 1A, 1B**). When FCCP and RuRed were combined, we observed a 20%  
29 decrease in cell viability with the 24-hour exposure ( $p=0.0001$ , via one-way ANOVA), but not in  
30 the 48-hour exposure (**Figure 1A, 1B**). It is possible that the combined exposure to FCCP and  
31 RuRed caused an initial inhibition of cellular function, but that the cells were able to recover  
32 over time.

33  
34 To determine if these co-exposures exacerbate the cytotoxicity of  $\text{Pb}^{2+}$ , we then  
35 conducted  $\text{Pb}^{2+}$  dose responses assessing cell viability at 0  $\mu\text{M}$ , 0.1  $\mu\text{M}$ , 2  $\mu\text{M}$ , 10  $\mu\text{M}$ , 25  $\mu\text{M}$ ,  
36 and 50  $\mu\text{M}$   $\text{Pb}^{2+}$  acetate concentrations either alone, in the presence of 5  $\mu\text{M}$  RuRed, in the  
37 presence of 1  $\mu\text{M}$  FCCP, or in the presence of both 5  $\mu\text{M}$  RuRed and 1  $\mu\text{M}$  FCCP. Following a  
38 24-hour exposure to  $\text{Pb}^{2+}$  alone, none of these doses resulted in cytotoxicity (**Figure 1C**). In a  
39 24-hour exposure to both  $\text{Pb}^{2+}$  and RuRed, we again observed no cytotoxicity (**Figure 1C**). The  
40 combination of  $\text{Pb}^{2+}$  and FCCP was also non-cytotoxic following 24 hours of exposure (**Figure**  
41 **1C**). However, a mixture of FCCP, RuRed, and  $\text{Pb}^{2+}$  resulted in a dose-dependent decrease in  
42 cell viability after 24 hours, with significant loss of cell viability at 25  $\mu\text{M}$  and 50  $\mu\text{M}$   $\text{Pb}^{2+}$  doses  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 (Figure 1C, 30%  $p=0.0067$  and 34%  $p=0.0256$ , respectively, via two-way ANOVA with  
4 Dunnett's post-hoc correction for multiple comparisons).

5  
6 Following a 48-hour exposure, we again observed no decrease in cell viability when cells  
7 were exposed to  $Pb^{2+}$  alone, or in combination with RuRed (Figure 1D). Interestingly, when  
8 cells were exposed to FCCP alongside  $Pb^{2+}$ , we observed a decrease in cell viability at the  
9 highest  $Pb^{2+}$  dose, 50  $\mu M$  (Figure 1D, 35%  $p=0.0111$ , via two-way ANOVA with Dunnett's  
10 post-hoc correction for multiple comparisons). Exposure to a mixture of all chemicals resulted in  
11 a significant decrease in cell viability at multiple  $Pb^{2+}$  concentrations (Figure 1D, 2  $\mu M$ : 12%,  
12  $p=0.0328$ , 10  $\mu M$ : 25%,  $p=0.0234$ , 25  $\mu M$ : 33%,  $p=0.0007$ , 50  $\mu M$ : 40%,  $p=0.0008$ , via two-way  
13 ANOVA with Dunnett's post-hoc correction for multiple comparisons).

14  
15 These data indicate that while FCCP and RuRed are not cytotoxic on their own at these  
16 concentrations, they can exacerbate the toxicity of  $Pb^{2+}$ . This highlights the importance of  
17 assessing toxicity in the presence of co-exposures, as seemingly non-cytotoxic compounds may  
18 be cytotoxic in combination with other chemicals. While the added concentrations of  $Pb^{2+}$   
19 selected for this study do not cause overt cell death on their own, they are associated with  
20 alterations in other markers of cellular health at these low levels<sup>14, 32-34</sup>. It is crucial that we  
21 understand how co-exposures may exacerbate specific cellular mechanisms that may lead to the  
22 observed additive toxicity. An in-depth knowledge of the pathways that become disrupted in the  
23 context of specific chemical mixtures is essential to the field of predictive toxicology in mixture  
24 work. In this study, we selected two mitochondrial toxicants that represent two different  
25 mechanisms of mitochondrial dysfunction: an uncoupler and an MCU inhibitor. The selection of  
26 compounds with distinct mitochondrial mechanisms allows us to test how the alterations of  
27 mitochondrial function in varying ways can impact  $Pb^{2+}$  toxicity. Using compounds with known  
28 mechanisms of action may allow us to infer the potential interactions of  $Pb^{2+}$  with other  
29 chemicals that have similar mechanisms of action. The increasing recognition and discovery of  
30 mitochondrial toxicants in the environment, including the increasing discovery and ubiquity of  
31 mitochondrial uncouplers<sup>26</sup>, supports the need to investigate how mitochondrial toxicants may  
32 interfere with seemingly well-understood legacy compounds, such as  $Pb^{2+}$ .

33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53 *FCCP and RuRed do not alter  $Pb^{2+}$  uptake into the mitochondria*  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

Given that FCCP and RuRed have previously been shown to alter  $\text{Ca}^{2+}$  uptake into the mitochondria<sup>23</sup>, we hypothesized that the exacerbated toxicity was due to differential uptake of  $\text{Pb}^{2+}$  into the mitochondria, as  $\text{Pb}^{2+}$  has been shown to enter the mitochondria through the same uniporter as  $\text{Ca}^{2+}$ <sup>21</sup>. To assess mitochondrial  $\text{Pb}^{2+}$  uptake, we exposed cells to their corresponding treatment for 48 hours, then performed a mitochondrial and cytosolic isolation and determined the  $\text{Pb}^{2+}$  concentrations in each fraction using ICP-MS.  $\text{Pb}^{2+}$  was below the limit of detection for all control samples, and elevated in treatments exposed to  $\text{Pb}^{2+}$ , in both the mitochondrial and cytosolic fractions (**Figure 2**), as expected. The concentration of  $\text{Pb}^{2+}$  did not vary significantly among treatments of 50  $\mu\text{M}$   $\text{Pb}^{2+}$  alone, 50  $\mu\text{M}$   $\text{Pb}^{2+}$  and FCCP, 50  $\mu\text{M}$   $\text{Pb}^{2+}$  and RuRed, and a mixture of all three chemicals in either the cytosolic or the mitochondrial fractions (**Figure 2A, 2B**). Additionally, we observed no differences in cytosolic  $\text{Ca}^{2+}$  levels across treatment groups, as well as no difference in cytosolic or mitochondrial levels of sodium and magnesium (**Figure S3**). This indicates that over the course of a 48-hour exposure, these treatments are not drastically altering the transport of analytes in and out of the mitochondria, despite their known influences on ion transport in short-term experiments. We were unable to directly measure mitochondrial  $\text{Ca}^{2+}$  levels in these samples, as the  $\text{Ca}^{2+}$  levels in the mitochondrial fractions were below the limit of detection. Since there were no significant differences in  $\text{Pb}^{2+}$  uptake, the differential toxicity observed is likely not driven by differences in cellular  $\text{Pb}^{2+}$  uptake. Other potential drivers of the observed increased cytotoxicity include alterations to membrane potential dynamics, differences in mitochondrial  $\text{Ca}^{2+}$  uptake, disruption in  $\text{Ca}^{2+}$  homeostasis, or alterations in bioenergetics, including oxygen consumption and ATP synthesis.

41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

While the cytotoxicity and uptake experiments involved dosing with  $\text{Pb}^{2+}$ -acetate stock solutions, the  $\text{Pb}^{2+}$  ions were most likely bound to proteins in the exposure medium, such as albumin from the fetal bovine serum (FBS). Prior research has shown that the amount of FBS will control free  $\text{Zn}^{2+}$  ion concentrations, resulting in altered bioaccessibility and cytotoxicity<sup>35</sup>. In our experiments, the FBS content in the media (10%) was constant. Thus, we interpret the observed internalization of  $\text{Pb}^{2+}$  to represent metal-ligand competition between matrix proteins and membrane transporter for  $\text{Pb}^{2+}$  ion uptake. Furthermore, the results suggest that the addition of FCCP and RuRed did not alter the bioaccessibility of  $\text{Pb}^{2+}$  and  $\text{Ca}^{2+}$  in the cell media, because

1  
2  
3 internalized levels of  $\text{Pb}^{2+}$  and other metals were similar for exposure mixtures (**Figures 2 and**  
4 **S3**).

5  
6 Previous reports have shown RuRed to inhibit entry of  $\text{Pb}^{2+}$  into the mitochondria;  
7 however, these experiments were done with shorter exposure times <sup>21</sup>. It is possible that upon  
8 binding to the MCU, RuRed initially inhibits  $\text{Pb}^{2+}$  from entering, but over the course of a 48-  
9 hour exposure, the RuRed comes on and off of the MCU, still allowing for the passage of  $\text{Pb}^{2+}$   
10 into the mitochondria. However, additional studies are needed to better understand the binding of  
11 RuRed to the MCU to confirm this. Additionally, it is possible that upon inhibition of the MCU,  
12 another channel or transporter also allows the influx of  $\text{Pb}^{2+}$  into the mitochondria <sup>36-38</sup>.  
13 Interestingly, previous reports suggested that  $\text{Pb}^{2+}$  may accumulate in the mitochondria <sup>14, 39</sup>,  
14 making this organelle particularly vulnerable to  $\text{Pb}^{2+}$  exposures. However, we observed similar  
15 levels of  $\text{Pb}^{2+}$  in the mitochondria and the cytosol. Additional work should be done to investigate  
16 the subcellular localization of  $\text{Pb}^{2+}$ .  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

### 27 *Calcium supplementation provides mild to no rescue of mixture cytotoxicity*

28  
29 While FCCP and RuRed did not disrupt  $\text{Pb}^{2+}$  entry into the mitochondria in our  
30 experiments, but are expected to disrupt calcium influx into the mitochondria <sup>23</sup>, it is possible  
31 that the observed mixture cytotoxicity was a result of disruption to mitochondrial calcium  
32 homeostasis. We attempted to test this directly, but unfortunately our results were inconclusive,  
33 because our samples contained  $\text{Ca}^{2+}$  levels that were below the limit of detection in  
34 mitochondria. However, if exposure to  $\text{Pb}^{2+}$  were limiting  $\text{Ca}^{2+}$  uptake into mitochondria and thus  
35 reducing cell viability, supplementing the media used to maintain the cells with additional  $\text{Ca}^{2+}$   
36 could potentially rescue this loss in cell viability. To address this question, we replicated our  
37 dose-response curves that indicated enhanced toxicity now with the addition of a  $\text{Ca}^{2+}$   
38 supplementation, in which the levels of  $\text{Ca}^{2+}$  present in the media were doubled.  
39  
40  
41  
42  
43  
44  
45

46 Previously we observed a greater than additive effect between 50  $\mu\text{M}$   $\text{Pb}^{2+}$  and FCCP  
47 after a 48-hour exposure, resulting in cytotoxicity (**Figure 1D**, in gray). To determine if elevated  
48  $\text{Ca}^{2+}$  would rescue the effect of FCCP and 50  $\mu\text{M}$   $\text{Pb}^{2+}$  on cytotoxicity, we assessed cell viability  
49 following a 48-hour exposure to FCCP, 50  $\mu\text{M}$   $\text{Pb}^{2+}$ , and  $\text{Ca}^{2+}$ . However, the addition of a  $\text{Ca}^{2+}$   
50 supplementation did not rescue the decrease in cell viability (**Figure S4**, analyzed via one-way  
51 ANOVA with Tukey's post-hoc test for multiple comparisons between FCCP and  $\text{Pb}^{2+}$  exposure  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 with the FCCP,  $Pb^{2+}$ , and  $Ca^{2+}$  exposure,  $p=0.4184$ ). Previously, we also observed decreases in  
4 cell viability across a range of  $Pb^{2+}$  doses following both a 24 and 48-hour exposure in  
5 combination with FCCP and RuRed (**Figure 1C**, **Figure 1D**, in green). Following the same  
6 exposure for 24 hours, but with the additional  $Ca^{2+}$  supplementation, there was no rescue of  
7 cytotoxicity as we observed a similar dose response curve and significant loss of cell viability at  
8 25  $\mu M$  and 50  $\mu M$   $Pb^{2+}$  doses (**Figure S5A**, 25  $\mu M$ : 25%,  $p=0.0381$  50  $\mu M$ : 35%,  $p=0.0399$ ,  
9 analyzed via one-way ANOVA with Tukey's post-hoc correction for multiple comparisons to the  
10 control).

11  
12 Following a 48 hour exposure with  $Ca^{2+}$  supplementation, there appears to be a mild  
13 rescue at the lower concentrations of  $Pb^{2+}$ , as evidenced by the lack of significant decrease in cell  
14 viability at  $Pb^{2+}$  concentrations of 2, 10, and 25  $\mu M$  (**Figure S5B**), but at 50  $\mu M$   $Pb^{2+}$ , there is no  
15 rescue as we still observe significant cytotoxicity (**Figure S5B**, 50%,  $p<0.0001$ , analyzed via  
16 one-way ANOVA with Tukey's post-hoc correction for multiple comparisons to the control).

17  
18 Overall, these results suggest that  $Ca^{2+}$  supplementation is likely not enough to fully  
19 rescue the increased cytotoxicity associated with these mixture exposures, though at some low  
20 doses in the 48-hour exposure, it does appear to alleviate cytotoxicity. While these findings do  
21 not completely disprove that  $Ca^{2+}$  supplementation could serve as a rescue, they do not offer  
22 robust support of this hypothesis. Future work should assess the  $Ca^{2+}$  dynamics following  
23 exposure to these mixtures and the extent to which supplementing cells with additional  $Ca^{2+}$   
24 influences  $Ca^{2+}$  levels in subcellular compartments.

### 35 36 37 38 39 *These mixtures do not strongly alter mitochondrial membrane potential*

40  
41 Because we saw no difference in mitochondrial  $Pb^{2+}$  uptake across exposures, we sought  
42 to determine if the mechanism driving elevated toxicity could be, in part, the collapse of the  
43 mitochondrial membrane potential (MMP). MMP, or  $\Delta\Psi_m$ , is the difference in electric potential  
44 across the inner and outer mitochondrial membranes. Under normal conditions, MMP is  
45 maintained by electron transport chain activity which pumps protons into the intermembrane  
46 space to establish the proton gradient required for ATP production<sup>40</sup>. FCCP can decrease MMP,  
47 as dissipation of the MMP results from uncoupling activity that allows protons to flow freely  
48 across the membrane, at uncoupler concentrations where that dissipation exceeds the capacity of  
49 the cell to increase proton pumping<sup>41, 42</sup>. It has previously been shown that  $Pb^{2+}$  decreases MMP  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 within hours of exposure <sup>32</sup>. On the other hand, previous reports have shown that Ru360, another  
4 MCU inhibitor, does not impact MMP <sup>43</sup>. However, proper function of the MCU is dependent on  
5 having an established mitochondrial membrane potential <sup>44</sup>. It is possible that the impact that  
6 FCCP exerts on MMP, combined with the additional stress of the inhibition of the MCU, results  
7 in elevated cytotoxicity in the context of Pb<sup>2+</sup> stress.  
8  
9

10  
11  
12 To determine if our exposure paradigm resulted not only in exacerbated cytotoxicity, but  
13 also decreased MMP, we examined membrane potential following 6-hour and 24-hour exposures  
14 to the same doses of Pb<sup>2+</sup> alone, or in combination with FCCP, RuRed, or both as described  
15 previously. TMRE is a dye whose uptake into the mitochondria is dependent on membrane  
16 potential; thus, higher fluorescence values are associated with increased membrane potential. We  
17 observed that at both the 6-hour and 24-hour timepoints, the 1 μM FCCP, 5 μM RuRed, and  
18 combination did not alter MMP, while our positive control (25 μM FCCP) did result in a  
19 reduction of the MMP, as expected (**Figure 3A, Figure 3B**).  
20  
21  
22  
23  
24  
25

26 To determine if these mitochondrial toxicants exacerbate the depolarization of the MMP  
27 when co-exposed with Pb<sup>2+</sup>, we then conducted Pb<sup>2+</sup> dose responses assessing MMP following  
28 the same exposure paradigms previously described. Following a 6-hour exposure to Pb<sup>2+</sup> alone,  
29 no alterations to MMP were observed (**Figure 3C**). In a 6-hour exposure to both Pb<sup>2+</sup> and  
30 RuRed, Pb<sup>2+</sup> and FCCP, and the combination of Pb<sup>2+</sup>, FCCP, and RuRed we again did not detect  
31 any differences in MMP (**Figure 3C**). Following a 24-hour exposure to increasing  
32 concentrations of Pb<sup>2+</sup> alone, we again observed no alterations in MMP induced by the mixtures  
33 of Pb<sup>2+</sup> and RuRed or a mixture of Pb<sup>2+</sup> and FCCP (**Figure 3D**). However, the mixture of all  
34 three compounds reveals a slight reduction in MMP at the highest Pb<sup>2+</sup> concentration of 50 μM  
35 (**Figure 3D**, 40% p=0.04, via two-way ANOVA with Dunnett's post-hoc correction for multiple  
36 comparisons).  
37  
38  
39  
40  
41  
42  
43  
44

45 Overall, our data indicates the MMP is not greatly disrupted by exposures to these  
46 mixtures. In addition, treatments associated with larger reductions in MMP are also associated  
47 with decreases in cell viability observed previously. We believe that reduction of MMP in these  
48 exposures may be contributing to the loss of cell viability, but given the modest levels of MMP  
49 reduction, we suspect that the mechanism driving the loss of cell viability is likely a combination  
50 of this decrease in MMP alongside other disruptions to cellular function. Further investigation is  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 necessary to determine the contributions of other cellular mechanisms that may contribute to the  
4 observed elevated cytotoxicity.  
5  
6  
7

### 8 **Conclusion:**

9  
10 In this study, we assessed  $\text{Pb}^{2+}$  toxicity in mixtures with two well-established  
11 mitochondrial toxicants with known mechanisms of action. We found that non-cytotoxic levels  
12 of  $\text{Pb}^{2+}$  became cytotoxic in mixtures with FCCP, or a combination of FCCP and RuRed.  
13 However, these co-exposures did not alter uptake of  $\text{Pb}^{2+}$  into the mitochondria. The mixture of  
14  $\text{Pb}^{2+}$ , FCCP, and RuRed was associated with mild decreases in MMP, which may contribute to  
15 the exacerbated cytotoxicity of these mixtures. Future work should assess alterations in  
16 mitochondrial calcium signaling and work to understand how co-exposures to compounds such  
17 as these that disrupt mitochondrial calcium homeostasis may also interfere with exposure to  
18 common toxicants such as  $\text{Pb}^{2+}$ , and result in elevated cytotoxicity.  
19  
20  
21  
22  
23  
24  
25

26 Exposure to chemicals of concern does not happen in isolation. A major barrier towards  
27 evaluating chemical risk is understanding the impacts of exposures occurring simultaneously and  
28 the interactions that may exacerbate or mitigate health impacts. Multiple exposures such as the  
29 mixtures presented in this study are important to consider as growing evidence suggests many  
30 environmental chemicals and pharmaceuticals can negatively impact mitochondrial function.  
31 Moving forward, it is imperative that we conduct co-exposure studies to understand how multi-  
32 chemical exposures will impact human and ecosystem health. Regulatory action for establishing  
33 “safe” levels of chemicals often does not have access to data representing how chemicals will act  
34 in mixtures with one another. It is important to consider relevant environmental mixtures of  
35 compounds that are often found together, as well as mixtures that contain chemicals with  
36 common mechanisms of action. Given that compounds may impact mitochondrial function in a  
37 number of different ways, we advocate for a tiered approach of testing compounds with  
38 unknown mechanisms in combination with a handful of compounds with known mechanisms.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

### 49 **Declaration of Interest Statement:**

50 The authors have no interests to declare.  
51  
52

### 53 **Acknowledgements:**

54 We would like to thank the Duke Superfund Center and Analytical Chemistry Core for their  
55 support throughout this project as well as Dr. Amy Herring for assistance with statistical tests.  
56  
57  
58  
59  
60

1  
2  
3 This work was supported by the National Science Foundation award GRFP DGE-1644868,  
4 NIEHS P42ES010356, and T32ES021432. Graphical abstract was created using Biorender.com.  
5  
6

### 7 **Author Contributions:**

8 Pooja Lalwani: conceptualization, investigation, formal analysis, writing – original draft.

9 Dillon E. King: conceptualization, investigation, formal analysis, writing – original draft.

10 Katherine Morton: conceptualization, formal analysis.

11 Nelson A. Rivera Jr: investigation, formal analysis.

12 Javier Huayta: formal analysis.

13 Heileen Hsu-Kim: project supervision, resources.

14 Joel N. Meyer: conceptualization, project supervision, resources, writing – review editing.  
15  
16  
17  
18

### 19 **List of Figures:**

20 **Figure 1.** Cell viability following 24- and 48-hour exposures to  $Pb^{2+}$ , FCCP, RuRed, and  
21 mixtures of the three.  
22

23 **Figure 2.** Mitochondrial and cytosolic  $Pb^{2+}$  uptake.

24 **Figure 3.** Mitochondrial membrane potential following 6- and 24-hour exposures to  $Pb^{2+}$ , FCCP,  
25 RuRed, and mixtures of the three.  
26

27 **Figure S1.** Chemical structures of RuRed and FCCP.

28 **Figure S2.** FCCP-induced mitochondrial uncoupling.


29 **Figure S3.** Analyte levels in mitochondrial and cytosolic fractions across treatment groups.

30 **Figure S4.** Calcium supplementation does not offer complete rescue of increased cytotoxicity in  
31 combination with FCCP.  
32

33 **Figure S5.** Calcium supplementation does not offer complete rescue of increased cytotoxicity in  
34 combination with FCCP and RuRed at 24 hours, but some protection at a 48-hour exposure to  
35 low doses of  $Pb^{2+}$ .  
36  
37  
38  
39


### 40 **Figure Legends:**

41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




**Figure 1.** Cell viability following 24- and 48-hour exposures to Pb<sup>2+</sup>, FCCP, RuRed, and mixtures of the three. **A)** Assessment of chemicals alone following a 24-hour exposure to FCCP (1 μM) and RuRed (5 μM) alone and in combination. Exposure to FCCP and RuRed in combination is associated with a decrease in cell viability (20%, p=0.001). **B)** Assessment of chemicals alone following a 48-hour exposure to FCCP (1 μM) and RuRed (5 μM) alone and in combination. For panels A and B, data was analyzed via one-way ANOVA with a Dunnett's post-hoc test for multiple comparisons of each group to the control (\*: p<0.05). **C)** 24-hour dose response comparing cell viability to Pb<sup>2+</sup> alone, Pb<sup>2+</sup> and RuRed, Pb<sup>2+</sup> and FCCP, Pb<sup>2+</sup> and FCCP and RuRed. Exposure to a mixture of all chemicals results in a significant decrease in cell viability at multiple Pb<sup>2+</sup> concentrations (25 μM: 30%, p=0.0067, 50 μM: 34%, p=0.0256). Data was analyzed via two-way ANOVA with a Dunnett's post-hoc test for multiple comparisons of each group to the control. Pb<sup>2+</sup> dose: p=0.003, Additional compound: p<0.0001, interaction: p=0.3513. (\*: p<0.05) **D)** 48-hour dose response comparing cell viability to Pb<sup>2+</sup> alone, Pb<sup>2+</sup> and RuRed, Pb<sup>2+</sup> and FCCP, Pb<sup>2+</sup> and FCCP and RuRed. Exposure to 50 μM Pb<sup>2+</sup> and FCCP resulted in a decrease in cell viability (35%, p=0.0111). Exposure to a mixture of all chemicals results in a significant decrease in cell viability at multiple Pb<sup>2+</sup> concentrations (2 μM: 12%, p=0.0328, 10 μM: 25%, p=0.0234, 25 μM: 33%, p=0.0007, 50 μM: 40%, p=0.0008). Data was analyzed via two-way ANOVA with a Dunnett's post-hoc test for multiple comparisons of each group to the control. Pb<sup>2+</sup> dose: p<0.0001, Additional compound: p<0.0001, interaction: p=0.0082. (\*: p<0.05). Fluorescence values recorded by the resazurin assay corresponding to the cell viability

have been normalized to the control group and are presented as a percentage of the control on all graphs.



**Figure 2.** Mitochondrial and cytosolic Pb<sup>2+</sup> uptake. **A)** Mitochondrial Pb<sup>2+</sup> concentrations across treatment groups determined by ICP-MS. Values are represented as ng Pb<sup>2+</sup> per μg of protein, as determined by a BCA assay. Data was analyzed via one-way ANOVA. **B)** Cytosolic Pb<sup>2+</sup> concentrations across treatment groups determined by ICP-MS. Values are represented as ng Pb<sup>2+</sup> per μg of protein, as determined by a BCA assay. Data was analyzed via one-way ANOVA.



**Figure 3.** Mitochondrial membrane potential (MMP) following 6- and 24-hour exposures to Pb<sup>2+</sup>, FCCP, RuRed, and mixtures of the three. **A)** Assessment of mitochondrial membrane potential following a 6-hour exposure to FCCP (1  $\mu$ M), RuRed (5  $\mu$ M), and a combination of FCCP and RuRed. A higher dose of FCCP (25  $\mu$ M) was used as a positive control. **B)** Assessment of mitochondrial membrane potential following a 24-hour exposure to FCCP (1  $\mu$ M), RuRed (5  $\mu$ M), and a combination of FCCP and RuRed. A higher dose of FCCP (25  $\mu$ M) was used as a positive control. For panels A and B, data was analyzed via one-way ANOVA with a Dunnett's post-hoc test for multiple comparisons of each group to the control (\*: p<0.05) **C)** Assessment of mitochondrial membrane potential following a 6-hour exposure to Pb<sup>2+</sup> alone, Pb<sup>2+</sup> and RuRed, Pb<sup>2+</sup> and FCCP, Pb<sup>2+</sup> and FCCP and RuRed. Data was analyzed via two-way ANOVA with a Dunnett's post-hoc test for multiple comparisons of each group to the control. Pb<sup>2+</sup> dose: p=0.6088, additional compound: p=0.6646, interaction: p=0.7792. **D)** Assessment of mitochondrial membrane potential following a 24-hour exposure to Pb<sup>2+</sup> alone, Pb<sup>2+</sup> and RuRed, Pb<sup>2+</sup> and FCCP, Pb<sup>2+</sup> and FCCP and RuRed. Data was analyzed via two-way ANOVA with a Dunnett's post-hoc test for multiple comparisons of each group to the control. Pb<sup>2+</sup> dose: p=0.1645, Additional compound: p=0.0079, interaction: p=0.716. Exposure to a mixture of all chemicals results in a significant decrease in MMP at the 50  $\mu$ M Pb<sup>2+</sup> concentration (40%, p=0.04).

## References:

1. H. Abadin, A. Ashizawa, Y. W. Stevens, F. Lladós, G. Diamond, G. Sage, M. Citra, A. Quinones, S. J. Bosch and S. G. Swarts, in *Toxicological Profile for Lead*, Agency for Toxic Substances and Disease Registry (US), Atlanta (GA), 2007.
2. A. M. Wade, D. D. Richter, C. B. Craft, N. Y. Bao, P. R. Heine, M. C. Osteen and K. G. Tan, *Environmental Science & Technology*, 2021, **55**, 7981-7989.
3. D. E. Jacobs, R. P. Clickner, J. Y. Zhou, S. M. Viet, D. A. Marker, J. W. Rogers, D. C. Zeldin, P. Broene and W. Friedman, *Environ Health Perspect*, 2002, **110**, A599-A606.
4. L. Patrick, *Altern Med Rev*, 2006, **11**, 2-22.
5. M. Edwards, S. Triantafyllidou and D. Best, *Environ Sci Technol*, 2009, **43**, 1618-1623.
6. D. Yeter, E. C. Banks and M. Aschner, *Int J Environ Res Public Health*, 2020, **17**.
7. K. S. Betts, *Environ Health Perspect*, 2012, **120**, a268-a268.
8. T. I. Lidsky and J. S. Schneider, *Brain*, 2003, **126**, 5-19.
9. H. Needleman, *Annual Review of Medicine*, 2004, **55**, 209-222.
10. M. A. Hassanien and A. M. E. Shahawy, Dordrecht, 2011.
11. M. Picard and O. S. Shirihai, *Cell Metabolism*, 2022, **34**, 1620-1653.
12. J. N. Meyer, M. C. K. Leung, J. P. Rooney, A. Sandoel, M. O. Hengartner, G. E. Kisby and A. S. Bess, *Toxicol Sci*, 2013, **134**, 1-17.
13. J. N. Meyer, J. H. Hartman and D. F. Mello, *Toxicol Sci*, 2018, **162**, 15-23.
14. L. Ma, J. Y. Liu, J. X. Dong, Q. Xiao, J. Zhao and F. L. Jiang, *Toxicol Res (Camb)*, 2017, **6**, 822-830.
15. A. Reddam, S. McLarnan and A. Kupsco, *Current Environmental Health Reports*, 2022, **9**, 631-649.
16. C. C. Bridges and R. K. Zalups, *Toxicol Appl Pharmacol*, 2005, **204**, 274-308.
17. C. Marchetti, *ISRN Toxicol*, 2013, **2013**, 184360.
18. T. J. B. Simons, *British Medical Bulletin*, 1986, **42**, 431-434.
19. A. Rădulescu and S. Lundgren, *Scientific Reports*, 2019, **9**, 14225.
20. J. M. Baughman, F. Perocchi, H. S. Girgis, M. Plovanič, C. A. Belcher-Timme, Y. Sancak, X. R. Bao, L. Strittmatter, O. Goldberger, R. L. Bogorad, V. Koteliansky and V. K. Mootha, *Nature*, 2011, **476**, 341-345.
21. S. C. Kapoor, G. D. V. Van Rossum, K. J. O'Neill and I. Mercorella, *Biochemical Pharmacology*, 1985, **34**, 1439-1448.
22. T. E. Gunter and D. R. Pfeiffer, *Am J Physiol*, 1990, **258**, C755-786.
23. C. Jean-Quartier, A. I. Bondarenko, M. R. Alam, M. Trenker, M. Waldeck-Weiermair, R. Malli and W. F. Graier, *Mol Cell Endocrinol*, 2012, **353**, 114-127.
24. J. J. Woods and J. J. Wilson, *Current Opinion in Chemical Biology*, 2020, **55**, 9-18.
25. A. S. Divakaruni, A. Paradyse, D. A. Ferrick, A. N. Murphy and M. Jastroch, in *Methods in Enzymology*, eds. A. N. Murphy and D. C. Chan, Academic Press, 2014, vol. 547, pp. 309-354.
26. A. Ebert and K.-U. Goss, *Toxicological Sciences*, 2021, **185**, 208-219.
27. S. Demine, P. Renard and T. Arnould, *Cells*, 2019, **8**.
28. L. Kamalian, A. E. Chadwick, M. Bayliss, N. S. French, M. Monshouwer, J. Snoeys and B. K. Park, *Toxicol In Vitro*, 2015, **29**, 732-740.
29. R. Swiss and Y. Will, *Curr Protoc Toxicol*, 2011, **Chapter 2**, Unit2.20.
30. R. Dulbecco and J. Elkington, *Proc Natl Acad Sci U S A*, 1975, **72**, 1584-1588.
31. J. H. Bae, J.-W. Park and T. K. Kwon, *Biochemical and Biophysical Research Communications*, 2003, **303**, 1073-1079.
32. M. H. Zarei, J. Pourahmad, M. Aghvami, M. Soodi and E. Nassireslami, *Main Group Metal Chemistry*, 2017, **40**, 105-112.

- 1  
2  
3 33. B. Han, D. García-Mendoza, H. van den Berg and N. W. van den Brink, *Environmental*  
4 *Toxicology and Chemistry*, 2020, **39**, 1060-1070.  
5 34. A. Dabrowska, J. L. Venero, R. Iwasawa, M. K. Hankir, S. Rahman, A. Boobis and N.  
6 Hajji, *Aging (Albany NY)*, 2015, **7**, 629-647.  
7 35. H. Haase, S. Hebel, G. Engelhardt and L. Rink, *Metallomics*, 2015, **7**, 102-111.  
8 36. X. Yang, B. Wang, H. Zeng, C. Cai, Q. Hu, S. Cai, L. Xu, X. Meng and F. Zou, *Brain*  
9 *Res*, 2014, **1575**, 12-21.  
10 37. C. M. Bisbach, R. A. Hutto, D. Poria, W. M. Cleghorn, F. Abbas, F. Vinberg, V. J.  
11 Kefalov, J. B. Hurley and S. E. Brockerhoff, *Sci Rep*, 2020, **10**, 16041.  
12 38. E. A. Belyaeva, T. V. Sokolova, L. V. Emelyanova and I. O. Zakharova,  
13 *ScientificWorldJournal*, 2012, **2012**, 136063.  
14 39. N. Castellino and S. Aloj, *Br J Ind Med*, 1969, **26**, 139-143.  
15 40. L. D. Zorova, V. A. Popkov, E. Y. Plotnikov, D. N. Silachev, I. B. Pevzner, S. S.  
16 Jankauskas, V. A. Babenko, S. D. Zorov, A. V. Balakireva, M. Juhaszova, S. J. Sollott  
17 and D. B. Zorov, *Anal Biochem*, 2018, **552**, 50-59.  
18 41. U. Hopfer, A. L. Lehninger and T. E. Thompson, *Proc Natl Acad Sci U S A*, 1968, **59**,  
19 484-490.  
20 42. R. Benz and S. McLaughlin, *Biophys J*, 1983, **41**, 381-398.  
21 43. W. Huang, C. Lu, Y. Wu, S. Ouyang and Y. Chen, *Journal of Experimental & Clinical*  
22 *Cancer Research*, 2015, **34**, 54.  
23 44. K. J. Kamer, Y. Sancak, Y. Fomina, J. D. Meisel, D. Chaudhuri, Z. Grabarek and V. K.  
24 Mootha, *Proc Natl Acad Sci U S A*, 2018, **115**, E7960-e7969.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60